Videos

Treatment involved repairing the brain tissue using HBOT, which led to significant symptom improvement.

Amanda Mixon, PA-C, discusses how rheumatic diseases may first present in skin, ocular or gastric symptoms.

A post hoc analysis of the MIRROR trial suggests comprehensive gout management should aim for remission, incorporating both uric acid lowering and broader symptom improvements.

Data showed a significant reduction in pain for patients with psoriatic arthritis and inadequate response to TNF treated with guselkumab compared with placebo.

Treatment with guselkumab led to rapid, clinically meaningful improvements in disease activity among patients with severe psoriatic arthritis, which were maintained through 2 years.

Results revealed cDAPSA can help providers accurately measure the level of disease activity in patients and predict whether the patient will have radiographic progression.

Daniel Blockmans, MD, PhD, discussed the results of a phase 3 trial that revealed upadacitinib significantly improved outcomes in patients with giant cell arteritis.

Amanda Mixon, PA-C, discusses the need to better bridge the rheumatology and dermatology care teams due to overlapping diseases.

Karen Costenbader, MD, discusses the 2 post hoc analyses that demonstrated treatment with belimumab reduces flares and increases response rates among patients with early active SLE.

Karen Costenbader, MD, discusses how early intervention with belimumab in patients with lupus significantly reduces disease flares and prevents irreversible organ damage.

Benjamin J. Smith, DMSc, PA-C, discusses the importance of defining comorbidities in diagnosing PsA, as well as prescribing biologics.

Nigil Haroon, MD, PhD, explains how understanding the "window of opportunity" is crucial in treating axial spondyloarthritis.

E. Michael Lewiecki, MD, discusses the significant treatment gap seen in osteoporosis and barriers to care.

In an interview with HCPLive, E. Michael Lewiecki, MD, explores the current principles of osteoporosis treatment.

Jason Busse, DC, PhD, discusses the discrepancies and contradictions across guidelines regarding the management of chronic pain.

Jason Busse, DC, PhD, highlights the modest benefits of opioids and therapeutic cannabis in managing chronic pain.

These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.

S Louis Bridges Jr, MD, PhD, explores the role of artificial intelligence in managing rheumatoid arthritis.

Benjamin Smith, DMSc, PA-C, discusses integrative rheumatoid arthritis treatment guidelines.

Jinny Tavee, MD, explains the potential neurological complications of sarcoidosis, an autoimmune disease that affects multiple systems.

Tracy Frech, MD, MSCI, explains what rheumatologists need to know about preventing and management digital ischemia.

Philip J Mease, MD, highlights recent data comparing the safety and efficacy of bimekizumab with other DMARDs for the treatment of PsA.

Manuel Litchman, MD, further discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

Manuel Litchman, MD, discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.

Judith Ng-Cashin, MD discusses Novotech's recent Rheumatoid Arthritis - Global Clinical Trial Landscape report.

John H Stone, MD, MPH, discusses the recent clinician-authored white paper from the Alliance for Patient Access: "Addressing Access Barriers for IgG4-RD Patients.”

In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.

In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.

In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.